In line with this, and because of the higher sensitivity and specificity of PSMA PET for the detection of micrometastatic disease, especially at low PSA levels, the current National Comprehensive Cancer Network and American Society of Clinical Oncology prostate cancer guidelines recommend PSMA PET (such as with 18F-flotufolastat, 18F-piflufolastat, or 68Ga-PSMA-11-PET) as a front-line imaging tool for patients with BCR or during initial staging or as a work-up for progressive disease and patient selection for PSMA radiopharmaceutical therapy (2,3). This evidence concerns the gene BCR and Familial prostate cancer.